---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-041049"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:43:26.998959+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics Q1 net loss widens to $3.8M; cash at $7.3M; tecarfarin development advances

## Summary
- Net loss of $3.8M for Q1 2025 vs $1.7M in Q1 2024; R&D expense $1.7M (up from $0.6M), G&A $2.3M (up from $1.1M).
- Cash and equivalents $7.3M at Mar 31, 2025, down from $10.0M at Dec 31, 2024; 1.9M common shares outstanding.
- Appointed Dr. James Ferguson as CMO in February 2025 to lead clinical development and business development.
- FDA Type D meeting in Feb 2025 provided guidance for Phase 3 tecarfarin trial; Abbott collaboration announced for TECH-LVAD trial.
- Completed API manufacturing transfer from Asia to U.S. CDMO; LVAD market research projects near doubling by 2032.

## SEC filing metadata
- accession: 0001213900-25-041049
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390025041049/0001213900-25-041049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390025041049/ea0241397-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-041049
- JSON: https://secwatch.observer/filing/0001213900-25-041049.json
- Plain text: https://secwatch.observer/filing/0001213900-25-041049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.